The bactericidal/permeability-increasing protein (BPI) inhibits the lipopolysaccharide (LPS)mediated activation of monocytes. Due to its inhibitory activity for various LPS, BPI has therapeutic potential in endotoxic shock. To be efficient in vivo, BPI should overcome the action of LPS-binding protein (LBP), a serum molecule that increases the expression of LPS-inducible genes via CD 14 of monocytes. rBPI 23 , a recombinant fragment of BPI, prevented in a dose-dependent manner the binding and the internalization of LPS mediated by LBP. Consequently, rBPI 23 also inhibited LPS-induced tumor necrosis factor (TN Fa) synthesis from monocytes. LPS-and LBP-mediated activation of monocytes was totally inhibited when LPS was preincubated with rBPI 23 • Adding rBPI 23 at the same time as LBP resulted in an important but partial inhibition of TNFa release, but this inhibition vanished with delaying the time of addition of rBPI 23 • These studies suggest that the inhibitory activity of BPI is related to its ability to compete with LBP for LPS.
Living organisms have developed several protective mechanisms against toxic lipopolysaccharide (LPS) of gram-negative bacteria. Very recently, two members ofa family of proteins have been recognized that possess LPS-binding sites. Indeed, the LPS-binding protein (LBP) and the bactericidalf permeability-increasing protein (BPI) share the ability to bind to smooth and rough LPS as well as to lipid A [1, 2] . There is a striking homology in the DNA sequence of the two human, rabbit, or bovine proteins [3] . However, despite their structural similarities, the functions of LBP and BPI appear an tagonistic.
Most circulating LPS binds to plasma LBP, and LPS linked to LBP is transferred to CD 14 on the surface of cells of the monocytic lineage and neutrophils, resulting in increased expression of LPS-inducible genes [3, 4] . LBP-mediated processes include increased tumor necrosis factor-a (TNFa) production by monocytes [3] [4] [5] , accelerated priming of neutrophils for the oxidative response to FMLP [6] , and increased adhesive capacity of complement receptor CR3 of neutrophils [7] . LBP was originally described as an acutephase reactant in the rabbit [8] , but its concentration in normal serum of rabbits, calves, mice, and humans [5] suggests that constitutive LBP is sufficient to bind concentrations of LPS usually found in infected hosts [4] .
BPI, a 55-kDa cationic protein found essentially in the azurophilic granules of polymorphonuclear leukocytes [9] , is specifically cytotoxic for gram-negative bacteria [10] . Soluble BPI, recombinant BPI, or its 25-kDa N-terminal fragment have been shown to inhibit endotoxin activity by neutralizing LPS, as detected by the inhibition of the proteolytic cascade in the limulus amebocyte lysate assay, by the inhibition of the priming of neutrophils by LPS, and by the inhibition of LPS-mediated production of TNFa by monocytes [11] [12] [13] .
Because of the apparent antagonistic properties of these two proteins that bind LPS, it is important to better define the respective roles of LBP and BPI in the LPS-induced activation process, inasmuch as BPI has therapeutic potential in endotoxic shock. We characterized in vitro the direct competition between LBP and BPI for binding ofLPS to cells of the monocytic lineage and investigated the competition between these two molecules in the activation process of monocytes resulting in TNFa release.
Materials and Methods
Materials. rBPI 23 [2] , a human recombinant NlIj-terminal fragment of BPI possessing LPS-neutralizing activity [14] , was obtained from XOMA (Berkeley, CA). Thaumatin (XOMA), used as a control protein, has a molecular weight and isoelectric point similar to rBPI 23 [2] . Murine LBP was prepared from serum. Murine LBP is a 61-kDa molecule that shares NlL-terminal sequence homology and functional properties with rabbit LBP and is able to present LPS to human monocytes [15] . Rab- was thus of interest to evaluate whether LPS-BPI complexes would also bind to CO 14 on monocytes or would interfere with the LBP-mediated binding of LPS through CD 14. Human monocytes incubated with 1 Jlg/mL FITC-0 III LPS in medium containing 4% albumin showed only a modest fluorescence (figure lA). In contrast, when cells were incubated with FITC-OIII LPS in the presence of 10% plasma, monocytes showed a distinctly brighter fluorescence (figure 1B). Preincubation of monocytes with MAb MY4 completely suppressed the plasma-mediated LPS binding ( figure 1C ) to the level of control monocytes incubated in the presence of albumin.
In our observations with 10% plasma, the concentration of LBP was 2 Jlg/mL. We added rBPI 23 to 10% plasma at a final concentration of 10 JLg/mL together with FITC-Olli LPS. The presence of rBPI 2 3 resulted in a decreased fluorescence (figure 10) compared with that observed with 10% plasma alone, indicating that less LPS had bound to monocytes. We then tested the effect of increasing concentrations of rBPI 2 3 in 10% plasma containing LBP on FITC-Olil LPS binding to monocytes, using FITC-0 III LPS concentrations from 10 ng/ml. to 1 JLg/mL, as described [5] (table I). The concentration ofrBPI 2 3 required for an efficient inhibition ofthe plasma-mediated binding of FITC-0 II 1 LPS to monocytes was dependent on the LPS concentration. With a weight ratio of 10: I (10 JLg/mL rBPI 2 3 Ẽb its were immunized with purified murine LBP, and immune IgG was purified by protein G chromatography. A control preparation of IgG was obtained from a polyclonal rabbit antiserum raised against murine recombinant interleukin-I.
LPS isolated from Escherichia coli 0 III, either unlabeled or labeled with fluorescein (FITC-O 111 LPS), was purchased from Sigma (St. Louis). MY4, a specific monoclonal antibody (MAb) recognizing human CDI4 [16] , was purchased from Coulter Immunology (Luton, UK).
Plasma was prepared from a pool of donors. The concentration of LBP in this pool was 20 Jlg/mL as measured by ELISA [17] (done by P. Tobias, Scripps Clinics, La Jolla, CA).
Test for LPS binding to monocytes. Heparinized human blood samples obtained from normal donors were used to prepare peripheral blood mononuclear cells (PBMC) by centrifugation over Ficoll-Paque (Pharrnacia, Uppsala, Sweden). PBMC ( (0 6 ) were incubated with I Jlg (alternatively, 10 or 100 ng) of FITC-01 11 LPS in I mL of RPM I enriched with 10%plasma or with 4% albumin as control. For CD 14 blockade, monocytes were pretreated with 10 Jlg/mL MY 4 MAb at 37°C After incubation for I h, the cells were washed twice with cold RPMI and analyzed using a FACScan flow cytometer with the LYSYS software package (Becton Dickinson, Basel, Switzerland). To restrict the analysis to monocytes, side scatter parameters were used for gating of the signal [18] .
Confocal laser microscopy. Human monocytes were purified from PBMC by adherence to plastic in 10%human serum for I h and recovered using a rubber policeman. Purity was >95% as assessed by morphology and nonspecific esterase staining. Monocytes were incubated with I Jlg/mL FITC-0 I 11 LPS in RPMI containing 4% albumin or 10% plasma for 30 min. After two washes, they were spun down using a cytocentrifuge (Cytospin 2; Shandon, Basel, Switzerland) for 3 min at 700 rpm. Slides were mounted in TRIS-glycerin-saline buffer and directly examined by fluorescence microscopy. Optical slices were generated in a Laser-Sharp MRC 500 confocal microscope (Bio-Rad Laboratories, Glattbrugg, Switzerland).
TNFa assays. PBMC (0.5 X (0 6 ) in 200 JlL of RPMI enriched with 10% plasma were added to each well of 96-well flat-bottom microtiter plates (Becton Dickinson). These preparations were stimulated with unlabeled 0111 LPS at various concentrations. Thaumatin or rBPI 2 3 at 10 Jlg/mL was added at various times relative to LPS exposure in plasma. Supernatants were collected for TNFa measurements after 4 h of culture at 37°C. Under the conditions used in this study, TNFa release by lymphocytes present in the PBMC fraction was negligible [19] . The cytotoxic activity of TNFa was measured on WEHI clone 13 cells as described [20, 21] .
Results
Effects of rBPI n on the LBP-mediated binding of FITe-DIll LPS to monocytes. We previously reported that plasma enhanced the binding of FITC-0 I I I LPS to human monocytes compared with binding observed with albumin alone. The enhancement in LPS binding was due to plasma LBP and was blocked by the MY4 anti-CD 14 MAb [5] . It observed in albumin was seen when rBPI 23 was added after antibody-mediated LBP blockade in plasma. These experiments thus confirmed that rBPI 23 did not promote the binding of FITC-O III LPS to monocytes but rather interfered with the LBP-mediated binding ofFITC-O III LPS to monocytes.
Effects of competition between purified murine LBP and rBPI 23for the binding ofFITC-Olll LPS to monocytes. We further investigated whether rBPI 23 could interfere with purified LBP for FITC-0 I I I LPS binding to monocytes. We used purified murine LBP for these experiments (table 2) . Effects ofrBPI2J on the internalization ofFITC-Olll LPS into human monocytes. To distinguish between cell surface binding and intracellular localization ofLPS, preparations of adherent monocytes were incubated with FITC-OIII LPS I~g murine LBP + I~g rBPI 2 3 rBPI 2 3 was observed. By increasing the weight ratio to 100: I (10 JLg/mL rBPI 23 with 100 ng/rnl. FITC-O III LPS), the plasma-mediated binding of LPS to monocytes was abolished.
In the presence or absence of rBPI 23 , the observed LPS binding was totally suppressed by CD 14 blockade by anti-CD 14 MAb. Control thaumatin did not affect the LBP-mediated binding of FITC-O III LPS by human monocytes (data not shown).
Effect of rBPI 23 on the binding of FITC-Olll LPS to human monocytes after LBP blockade in plasma. The observations reported above indicated that rBPI 23 inhibited the plasma-mediated binding ofLPS by monocytes in a dose-dependent manner. When FITC-OIII LPS was used at a 1-JLg/mL concentration, residual binding was found despite the presence of 10 JLg/mL rBPI 23 (table I) . This binding was suppressed by CD 14 blockade. We then investigated whether this residual binding was due to LBP or to BPI. We used murine plasma for these experiments, because we had an anti-murine LBP antibody readily available and because murine LBP is able to present LPS to human CDI4 in a fashion identical to that of human LBP [5, 15] . LBP was blocked in murine plasma with a rabbit anti-murine LBP IgG fraction. An irrelevant rabbit IgG fraction directed against murine interleukin-I was used as control. In the presence of control murine plasma, LBP was able to increase the binding of FITC-0 I I I LPS to human monocytes over that to control monocytes incubated in albumin (figure 2). This binding was suppressed by antibody-mediated LBP blockade and, t.o a lesser extent, by the addition of rBPI 23 • The preincubation of monocytes with anti-CD 14 MAb MY 4 suppressed LBP-mediated binding of FITC-0 III LPS. No increase in binding of FITC-0 I I I LPS to monocytes over that JID 1993;167 (June) Figure 3 . Effects of recombinant bactericidal/permeability increasing protein (rBPI 23 ) on LPS binding protein (LBP)-mediated internalization of fluorescein-labeled Escherichia coli 0 III LPS by human monocytes. Incubation medium contained 4% albumin (a); 10% human plasma (b); 10%plasma after pretreatment ofmonocytes with anti-CD 14 monoclonal antibody (c); 10% human plasma and rBPI 23 that was preincubated with LPS for 5 min (d); rBPI 23 added concurrently with 10%plasma and monocytes (e); rBPI 23 added 5 min after mixture of monocytes, 10%plasma, and LPS (f). Fluorescence of monocytes was visualized in confocal microscope after 1 h of incubation. and analyzed by confocal microscopy, which allows observation of subsurface structures. Monocytes were scanned in depth at various focal planes. Through-focus images were similar, and figure 3 is representative of one focal plane. When monocytes were incubated for I h with I Jlg/mL FITC-OIII LPS in 4% albumin (figure 3a), no fluorescence was detectable. When incubation medium contained 10% human plasma, the fluorescence observed was cytoplasmic (figure 3b). When FITC-OIII LPS was added to anti-CD 14-treated monocytes in the presence of 10% plasma, fluorescence was abolished (figure 3c). When FITC-Olll LPS was preincubated with 10 Jlg/mL rBPI 23 before adding human plasma as a source of LBP, no fluorescence was detectable ( figure 3d ). However, when rBPI 23 was added at the same time as plasma LBP (figure 3e) or 5 min thereafter (figure 3f), the uptake of FITC-O III LPS into monocytes was only partially prevented. At concentrations < 10 Jlg/mL, rBPI 2 3 was unable to suppress the fluorescence in these experiments (data not shown).
Time-dependent inhibition by rBPI 23 of the LBP-mediated binding ofFITC-Olll LPS to human monocytes. We previously reported that the LBP-mediated binding of FITC-0111 LPS by monocytes is a rapid process largely completed in 5-15 min [5] . Thus, in the next set of experiments, we added rBPI 2 3 at various times relative to FITC-0 I I I LPS exposure in plasma (figure 4). When LPS was first preincubated with rBPI 2 3 30 min or 5 min before being added to monocytes in medium containing plasma, LBP-mediated binding ofFITC-O III LPS to monocytes was virtually abolished. When LPS and rBPI 23 were added without preincubation together with monocytes in 10% plasma, rBPI 23 was still able to inhibit LPS binding to monocytes. The addition of rBPI 23 from 5 to 30 min after the initiation of the reaction of plasma LBP with FITC-O III LPS progressively reduced the
Discussion
The focus of this investigation was to assay the direct competition between BPI and LBP for LPS binding to monocytes. Indeed. since BPI appears to be an efficient neutralizing agent of LPS [11] [12] [13] , it should in vivo be able to overcome the action of LBP, which amplifies the effects of LPS on both monocytes and neutrophils [3] [4] [5] [6] [7] .
The experiments were first conducted in plasma containing LBP using a high LPS concentration (I tLg/mL). By both flow cytometry and confocal microscopy, we observed that rBPI 2 3 • a recombinant Nl-ly-rerminal fragment of BPI [2, 14] , reduced LPS binding to monocytes when added to normal plasma containing LBP. Low residual LPS binding was observed. which was suppressed by CD I4 blockade. Since binding of LPS to monocytes in the presence of plasma is mediated by the formation of LPS-LBP complexes that bind to CD 14 receptors [3] . these observations demonstrate that the small residual LPS binding in the presence of a suboptimal concentration of rBPI 23 was most likely due to LBP. Thus, rBPI 23 was able to prevent the formation of LPS-LBP complexes and their subsequent binding to human monocytes, although the inhibition was not complete at a high concentration of 1 tLg/mL LPS. Furthermore, when LBP in plasma was functionally blocked by specific antibodies. rBPI 2 3 was not able to present LPS to CD I 4 of monocytes. Confocal microscopy, which allows the observation of subsurface structures. confirmed that rBPI 23 prevented the LBP-mediated internalization of LPS through CD I4.
At LPS concentrations of 100 and 10 ng/rnl., a 100: I weight ratio of rBPI 23 to LPS appeared necessary to suppress the LBP-mediated binding of LPS in plasma. The relative concentrations of LPS. BPI, and LBP appeared thus to play an important role. When similar amounts ofrBPI 2 3 (43 nM) and purified murine LBP ( I 6 nM) were added to monocytes in the presence of 100 ng/mL LPS, rBPI 2 3 appeared able to completely suppress the LBP-mediated binding of LPS to monocytes. These data indicate that a 3-fold molar excess of rBPI 23 has a potent inhibitory effect on LPS in direct competition with LBP. The concentration ofLBP in pooled plasma used in these experiments was 20 tLg/mL. as measured by ELISA [17] . In our observations with 10% plasma, the concentration of LBP was 2 tLg/mL, that is. 33 nM. To completely suppress the LBP-mediated binding of 10 ng/mL LPS, 10 tLg/mL rBPI 23 , or 430 nM, was necessary. This observation thus suggests that in plasma at least a IO-fold molar excess of rBPI 23 should be necessary to overcome totally the action of LBP.
Our experiments showed in addition that the rBPI 2rme-data not shown) after exposure to LPS resulted in unhampered TNFa release compared with that seen in controls incubated with thaumatin. This was shown by adding rBPI 2 3 for a period of I h, 1 h after FITC-0 I I I LPS had reacted with monocytes in 10% plasma. In this setting, the addition of rBPI 2 3 for a prolonged period did not modify the fluorescence pattern (data not shown). Control thaumatin had no effect on the LBP-mediated binding of FITC-O I II LPS by human monocytes. Effects ofrBPI 23 on the LPS-mediated TNFa release by human nionocvtes in medium containing plasma. Having observed that rBPI 2 3 efficiently blocked LPS binding in a timedependent manner, we added rBPI 2 3 to 10% plasma at various times relative to LPS exposure, and TNFa was measured in the supernatants after 4 h (figure 5). When LPS (either 100 pg/rnl. or 1 ng/mL) was first incubated with rBPI 2 3 for 5 min before being added to plasma, virtually no TNFa was detectable in the supernatant after 4 h. rBPI 23 was still able to inhibit TNFa production, although partially, when added together with LPS. This inhibition of TNFa vanished when LPS concentrations> 1 ng/ml. were used. Delaying the time of addition of rBPl 2 3 for 5 min (or more, 
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I0 BPI • Thaumatln I diated inhibition of LBP-LPS binding to monocytes was more efficient when rBPI 23 could interact with LPS before in terference with LBP. Indeed, rBPI 23 was unable to reverse the LBP-mediated binding of LPS to monocytes. This was observed in experiments using flow cytornetry, confocal microscopy, and monocyte activation measured by TNFa release, thus extending and confirming a similar study with the native nonrecombinant protein [12] . This observation indicated that a concentration of 10 jLg/mL rBPI 23 was sufficient to totally inhibit the production of TN Fa mediated by either 100 pg/rnl. or I ng/mL LPS. rBPI 23 was still able to inhibit TNFa release when added at the same time as LBP, but the inhibition was not complete. However, delayed addition of rBPI 23 respective to LBP failed to inhibit TNFa release, an observation consistent with the hypothesis that a few minutes of interaction of the LPS-LBP complex with monocyte CD 14 could be sufficient to trigger cytokine production.
In conclusion, under the conditions of our assays-I 0% plasma containing LBP-we can conclude that rBPI 23 competed with but did not totally suppress the LBP-mediated effects of LPS. Indeed, if rBPI 23 appeared able to block the LBP-mediated binding of LPS to monocytes as revealed in our binding assays, this apparent blockade did not totally suppress TNFa production. Additional studies should be done in vitro using whole blood or other sources of LPS to confirm these observations. Thus, our studies showed that rBPI 23 was very effective as an inhibitor of LPS on monocytes, provided it was used prophylactically. Further studies in vivo are needed to investigate whether rBPI 23 could overcome the LPS-mediated activation of the host.
